Home › Opioid Overdose › NCT07778394

Personalized Addiction Treatment enHancement

The Vira Platform: A Contextually Triggered Just-in-Time Adaptive Intervention for Opioid Use Disorder

Who can join

Ages 22 and older · All sexes

Inclusion Criteria:

* Age 22+
* Current Opioid Use Disorder diagnosis
* Prescribed buprenorphine or methadone
* Initiated or reinitiated buprenorphine or methadone treatment recently
* Access to personal smartphone

Exclusion Criteria:

* Not fluent in English
* Limited mental capacity or inability to provided informed consent

About the study

Many patients stop medication-based treatments for Opioid Use Disorder (OUD) prematurely, placing them at increased risk for overdose and death. Providing targeted interventions for OUD, particularly through an accessible, digital health platform, is a potential way to enhance recovery and keep patients engaged in care. The current study seeks to test whether a digital mental health platform, delivered by peer recovery support specialists to individuals prescribed buprenorphine or methadone medication, will improve treatment outcomes for this high risk population.

What is being tested

• Vira Platform (behavioral)
• Treatment-As-Usual (behavioral)

Sponsor: Rhode Island Hospital · Participants: 40 · Started: Aug 13, 2026

Contact the study team

• Susan Ramsey, PhD · Phone: 401-444-7831
• Evan Ames · Phone: 401-444-2474

Official record on ClinicalTrials.gov — NCT07778394

Locations in the U.S.

Conditions

• Opioid Overdose

From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.